The role of miRNA-133b and its target gene SIRT1 in FAP-derived desmoid tumor.
B-catenin
Wnt pathway
desmoid tumor
familial adenomatous polyposis
miRNA
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
30 Jun 2020
30 Jun 2020
Historique:
received:
18
03
2020
accepted:
14
05
2020
entrez:
14
7
2020
pubmed:
14
7
2020
medline:
14
7
2020
Statut:
epublish
Résumé
Signaling pathways have a key role in driving the uncontrolled development of familial adenomatous polyposis (FAP)- associated and sporadic desmoid tumors (DTs). The relationship between the Wnt/b-catenin signaling pathway and DTs has been extensively studied, but no reliable biomarkers able to detect their histological subtype have been identified for the accurate diagnosis. In this study we studied the differences in miRNA expression between sporadic (20 patients) and FAP-associated DTs (7 patients) using microarray confirmed by quantitative PCR (qPCR). The analysis showed 19 dysregulated miRNAs. Among them miR-133b levels were significantly lower in FAP-associated DT than in sporadic DT. Therefore, two mRNAs, associated to miR-133b and β-catenin expression, the SIRT1 and ELAVL1were analyzed. The qPCR analysis showed that SIRT1 mRNA levels were significantly up-regulated in FAP-associated DT than in sporadic DT, whereas no differences in ELAVL1 expression was observed between these two DT types. In addition, a negative correlation was observed between miR-133b and SIRT1 in FAP-associated DTs, but not in sporadic DTs. The miR-133b-SIRT1-β-catenin axis may represent a novel mechanism underlying progression of FAP-associated DT.
Identifiants
pubmed: 32655835
doi: 10.18632/oncotarget.27622
pii: 27622
pmc: PMC7335664
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2484-2492Informations de copyright
Copyright: © 2020 Rotelli et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST None.
Références
Oncol Res. 2017 Nov 2;25(9):1421-1430
pubmed: 28059051
Stem Cell Res Ther. 2019 Dec 16;10(1):381
pubmed: 31842978
Exp Cell Res. 2016 May 1;343(2):135-147
pubmed: 27090017
J Exp Clin Cancer Res. 2016 Apr 14;35:67
pubmed: 27074866
Ann Surg. 1999 Jun;229(6):866-72; discussion 872-3
pubmed: 10363901
Cancer Res. 2012 Jan 1;72(1):346-55
pubmed: 22094874
Front Pharmacol. 2019 Jan 30;10:38
pubmed: 30761005
Int J Mol Sci. 2015 Jun 05;16(6):12773-90
pubmed: 26057746
Oncotarget. 2017 Jul 25;8(30):50193-50208
pubmed: 28422730
Biochem Biophys Res Commun. 2015 Jan 30;457(1):65-70
pubmed: 25534855
PLoS One. 2013 Jun 14;8(6):e66283
pubmed: 23799088
J Surg Oncol. 2017 Nov;116(6):716-721
pubmed: 28570749
JAMA Oncol. 2019 Apr 1;5(4):567-568
pubmed: 30703188
Cancer Sci. 2015 May;106(5):650-5
pubmed: 25707497
Oncotarget. 2016 Jun 14;7(24):36247-36254
pubmed: 27166997
Eur J Cancer. 2016 May;58:90-6
pubmed: 26974708
Front Nutr. 2019 Sep 25;6:148
pubmed: 31608282
Genes Chromosomes Cancer. 2015 Oct;54(10):606-15
pubmed: 26171757
Virchows Arch. 2015 Aug;467(2):203-10
pubmed: 25838078
Eur J Pharmacol. 2018 Oct 15;837:96-104
pubmed: 30125566
EMBO Mol Med. 2013 Mar;5(3):430-40
pubmed: 23364955
Cancer Biomark. 2017 Jul 4;19(4):425-436
pubmed: 28582847
Cancer Med. 2016 Aug;5(8):1856-62
pubmed: 27292588
Clin Sci (Lond). 2014 Sep;127(5):341-50
pubmed: 24641356
J Bone Miner Res. 2019 Jun;34(6):1169-1181
pubmed: 30690778
PLoS One. 2010 Oct 05;5(10):
pubmed: 20957151
Anticancer Res. 2017 Jul;37(7):3357-3366
pubmed: 28668823
Ann Rheum Dis. 2016 Jan;75(1):226-33
pubmed: 25180292
Stem Cells Transl Med. 2017 Dec;6(12):2115-2125
pubmed: 29072369
Clin Cancer Res. 2014 May 1;20(9):2312-25
pubmed: 24610824
Int J Cancer. 2011 Jul 1;129(1):256-61
pubmed: 20830713
Eur J Cancer. 2020 Mar;127:96-107
pubmed: 32004793
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Ann Oncol. 2017 Oct 1;28(10):2399-2408
pubmed: 28961825
Oncotarget. 2017 Jul 12;8(38):63935-63948
pubmed: 28969042
Am J Pathol. 2008 Nov;173(5):1518-27
pubmed: 18832571
Cancer Lett. 2019 Oct 28;463:1-10
pubmed: 31394122
Mod Pathol. 2013 Apr;26(4):563-71
pubmed: 23196799
Oncotarget. 2017 Jun 27;8(26):41866-41875
pubmed: 28418912
Eur J Surg Oncol. 2009 Jan;35(1):3-10
pubmed: 18722078
J Cell Physiol. 2013 Jun;228(6):1344-50
pubmed: 23169148
Cancer Res. 2010 Oct 1;70(19):7690-8
pubmed: 20841474
Oncoscience. 2016 Jun 30;3(5-6):173-85
pubmed: 27489864